MacroGenics
Manufacturing · Maryland, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
9704 Medical Center Dr, Rockville, Maryl...Phone Number
(301) 251-5172Website
www.macrogenics.comRevenue
$157.1 MillionStock Symbol
MGNXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About MacroGenics
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The combination of MacroGenics' technology platforms and protein engineering has allowed the Company to generate product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.Explore more
MacroGenics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MacroGenics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once MacroGenics has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at MacroGenics
Click to see if MacroGenics had a recent Job posting/layoffs
MacroGenics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if MacroGenics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when MacroGenics launches new products
Check out if MacroGenics is spiking on competitors!
Earning: See what the market has to say on MacroGenics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to MacroGenics
Compare insights from companies similar to MacroGenics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
MacroGenics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MacroGenics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MacroGenics.
MacroGenics financials insights
Gather financial insights about MacroGenics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series D
$25M
2010
Grant
$9.8M
2013
Stock Offering
$83.8M
2014
Stock Offering
$76.7M
2015
Stock Offering
$141M
2017
Stock Offering
$23.6M
2018
Stock Offering
$110M
MacroGenics Tech Stack
A closer look at the technologies used by MacroGenics
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
MacroGenics is planning to move offices in July 2026. The move will impact approximately 135 employees at the existing office located at 9704 Medical Center Dr, Rockville, MD.
Facilities Relocation/Expansion
Open Position
Partnership
MacroGenics has a multi-program collaboration with Gilead encompassing three active programs including a CD123-targeting bispecific for AML, MDS, and other CD123-positive hematologic malignancies with approximately $1.7 billion in potential milestones and approximately $100 million already collected. Gilead holds options to assume development responsibility for each program at predefined decision points.
Partnership
Partnership
MacroGenics has an amended ZYNYZ royalty agreement with Incyte, under which Incyte reported Q1 sales of approximately $40 million a tenfold increase year-over-year following additional approvals for frontline anal cancer in the US, Europe, and Japan.
Contracts
Pain Point
Clinical Operations
MacroGenics News & Media
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics’ good manufacturing practice (GMP) drug substance manufacturing operations to Bora.MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration’s (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 yMacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates
MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical updates across its oncology pipeline. Speaking during an informal discussion hosted by Stifel seniMacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding MacroGenics
Sign Up For FreeTo access detailed company insights
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The combination of MacroGenics' technology platforms and protein engineering has allowed the Company to generate product candidates and enter into several strategic collaborat... Read More
